Ruxolitinib in Treating Participants With Chronic Myeloid Leukemia With Minimal Residual Disease While on Therapy With Tyrosine Kinase Inhibitors
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Dana-Farber Cancer Institute
OHSU Knight Cancer Institute
Barbara Ann Karmanos Cancer Institute
St. Jude Children's Research Hospital
Barbara Ann Karmanos Cancer Institute
Northwestern University
M.D. Anderson Cancer Center
Bristol-Myers Squibb
University of Massachusetts, Worcester
Duke University
Merck Sharp & Dohme LLC
National Cancer Institute (NCI)
Bristol-Myers Squibb